Caveolin-1 expression during the progression of pulmonary hypertension

Experimental Biology and Medicine

Volumn 237, Issue 8, 2012, Pages 956-965

  Huang, Jing ^a   Wolk, John H ^a   Gewitz, Michael H ^a   Mathew, Rajamma ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Caveolin 1; Endothelial cells; Pulmonary hypertension; Smooth muscle cells; vWF

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CAVEOLIN 1; CD31 ANTIGEN; GELATINASE A; GUANYLATE CYCLASE; MONOCROTALINE; PROTEIN BCL XL; STAT3 PROTEIN; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; HEART RIGHT VENTRICLE HYPERTROPHY; LUNG BLOOD VESSEL; MALE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; SMOOTH MUSCLE FIBER; SYSTOLIC BLOOD PRESSURE;

ANIMALS; CAVEOLIN 1; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HYPERTENSION, PULMONARY; LUNG; MALE; MATRIX METALLOPROTEINASE 2; MONOCROTALINE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84865313805     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1258/ebm.2012.011382     Document Type: Article

References (47)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Galdwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54
2. Badesch DB, Raskob GE, Elliott G, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension. Baseline characteristics from the REVEAL registry. Chest 2010;137:376-87
3. Selimovic N, Bergh CH, Andersson B, Sakiniens E, Carlsten H, Rundquist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34:662-8
4. Mathew R, Zeballos G, Tun H, Gewitz MH. Role of nitric oxide and endothelin 1 imbalance in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995;30:739-46
5. Mathew R, Huang J, Katta UD, Krishnan U, Sandoval C, Gewitz MH. Immunosuppressant-induced endothelial damage and pulmonary arterial hypertension. J Ped Hem Onc 2011;33:55-8
6. Mathew R, Huang J, Shah M, Patel K, Gewitz MH, Sehgal PB. Disruption of endothelial-cell caveolin-1 alpha/raft scaffolding during the development of monocrotaline-induced pulmonary hypertension. Circulation 2004;110:1499-506
7. Huang J, Wolk JH, Gewitz MH, Mathew R. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Expt Lung Res 2010;36:57-66
8. Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH, Gewitz MH, Mathew R. Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol 2008;294:L1250-L1259
9. Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A. Effects of monocrotaline on eNOS expression and sulfhydryl levels in rat lungs heart disease 2002;4:152-8
10. Liu P, Rudick M, Anderson RGW. Multiple functions of caveolin-1. J Biol Chem 2002;277:41295-8
11. Couet J, Li S, Okamoto T, Ikezu T, Lisanti MP. Identification of peptide and protein ligand for the caveolin-1 scaffolding domain. Implications for the interaction of caveolin and caveolae associated proteins. J Biol Chem 1997;272:6535-3
12. Okamoto T, Schlegel A, Scherer PE, Lisanti MP. Caveolins, a family of scaffolding proteins for organizing pre-assembled signaling complexes at the plasma membrane. J Biol Chem 1998;273:5419-22
13. Mathew R. Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulm Med 2011;2011:573432
14. Galbiati F, Volonté D, Liu J, Capazzo F, Frank PG, Zhu L, Pestell RG, Lisanti MP. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/ Cip1)-dependent mechanism. Mol Biol Cell 2001;12:2229-44
15. Torres VA, Tapia JC, Rodríguez DA, Párraga M, Lisboa P, Montoya M, Leyton L, Quest AF. Caveolin-1 controls cell proliferation and cell death by suppressing expression of the inhibitor of apoptosis protein survivin. J Cell Sci 2006;119:1812-23
16. Hardin CD, Vallejo J. Caveolins in vascular smooth muscle: form organizing function. Cardiovasc Res 2006;69:808-15
17. Kawut SM, Horn EM, Berekashvili KK, Widlitz AC, Rosenzweig EB, Barst RJ. Von Willebrand factor independently predicts long-term survival in patients with pulmonary arterial hypertension. Chest 2005;128:2355-62
18. Smadja DM, Gaussem P, Mauge L, Israel-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhé PR, Bonnet D, Lévy M. Circulating endothelial cells: a new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 2009;119:374-81
19. Patel HH, Zhang S, Murray F, Suda RY, Head BP, Yokoyama U, Swaney JS, Niesman IR, Schermuly RT, Pullamsetti SS, Thistlethwaite PA, Miyanohara A, Farquhar MG, Yuan JX, Insel PA. Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. FASEB J 2007;21:2970-9
20. Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A, Humbert M, Adnot S, D'Ortho MP, Lafuma C. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J 2005;25:834-42
21. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, Daniel EE, Schulz R. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 2007;42:896-901
22. Mathew R, Gloster ES, Sundararajan T, Thompson CI, Zeballos G, Gewitz MH. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. J Appl Physiol 1997;82:1493-8
23. Mathew R, Guzowski DE, Gloster ES. Effect of verapamil on monocrotaline-induced pulmonary artery hypertension and endothelial cell dysfunction in rats. Exp Lung Res 1990;16:627-44
24. Linder AE, McCluskey LP, Cole KR 3rd, Lanning KM, Webb RC. Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J Pharmacol Exp Ther 2005;314:9-15
25. Mathew R, Huang J, Gewitz MH. Pulmonary artery hypertension: caveolin-1 and eNOS interrelationship: a new perspective. Cardiol Rev 2007;15:143-9
26. Jasmin JF, Mercier I, Dupuis J, Tanowitz HB, Lisanti MP. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy. Circulation 2006;114:912-20
27. Frank PG, Woodman SE, Park DS, Lisant MP. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 2003;23:1161-8.
28. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED. Gene therapy targeting surviving selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91
29. Mathew R. Inflammation and pulmonary hypertension. Cardiol Rev 2010;18:67-72.
30. Jasmin JF, Mercier I, Sotgia F, Lisanti MP. SOCS proteins and caveolin-1 as negative regulators of endocrine signaling. Trends Endocrinol Metab 2006;17:150-8
31. Chiu WT, Lee HT, Huang FJ, Aldape KD, Yao J, Steeg PS, Chou CY, Lu Z, Xie K, Huang S. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition. Cancer Res 2011;71:4932-43
32. Ewenstein BM, Warhol MJ, Handin RI, Pober JS. Composition of the von Willebrand factor storage organelle (Weibel Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol 1987;104:1423-33
33. Collados MT, Sandoval J, Lopez S, Massó FA, Páez A, Borbolla JR, Montaño LF. Characterizationof vonWillebrand factor inprimary pulmonary hypertension. Heart Vessels 1999;14:246-52
34. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 1997;34:255-65
35. Kumpers P, Nickel N, Lukasz A, Golpon H, Westerkamp V, Olsson KM, Jonigk D, Maegel L, Bockmeyer CL, Dacid S, Hoeper MM. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:2291-30
36. Hassan GS, Williams TM, Frank PG, Lisanti MP. Caveolin-1-deficient aortic smooth muscle cells show cell autonomous abnormalities in proliferation, migration, and endothelin-based signal transduction. Am J Physiol 2006;290:H2393-H2401
37. Isshiki M, Anderson RG. Function of caveolae in Ca2+ entry and Ca2+-dependent signal transduction. Traffic 2003;4:717-23
38. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth R, Sydkov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21
39. Yamamoto M, Toya Y, Jensen RA, Ishikawa Y. Caveolin-1 is an inhibitor of platelet-derived growth factor receptor signaling. Expt Cell Res 1999;247:380-8
40. Kawabe J, Okumura S, Lee MC, Sadoshima J, Ishikawa Y. Translocation of caveolin regulates stretch-induced ERK activity in vascular smooth muscle cells. Am J Physiol 2004;286:H1845-H1852
41. Sedding DG, Braun-Dullaeus RC. Caveolin-1: dual role for proliferation of vascular smooth muscle cells. Trends Cardiovasc Med 2006;16:50-5
42. Kuzuya M, Kanda S, Sasaki T, Tamaya-Mori N, Cheng XW, Itoh T, Itohara S, Iguchi A. Deficiency of gelatinase A suppresses smooth muscle invasion and development of experimental intimal hyperplasia. Circulation 2003;108:1375-81
43. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000;105:21-34
44. Emonard H, Hornebeck W. Binding of 92 kDa and 72 kDa progelatinases to insoluble elastin modulates their proteolytic activation. Biol Chem 1997;378:265-71
45. Annabi B, Lachambre M, Bousquet-Gagnon N, Pagé M, Gingras D, Béliveau R. Localization of membrane type 1 metalloproteinase in caveolae membrane domains. Biochem J 2001;353:547-53
46. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res 2006;69:614-24
47. Pauly RR, Passanti A, Bilato C, Monticone R, Cheng L, Papadopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994;75:41-54.